ResearcherUniversity of HelsinkiActive in the last 2 years
Anna Maria Nurmi
Matched on ORCID iD 0000-0003-2235-1752; OpenAlex author ID A5060959183. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 1 paper
Papers 8
- Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-14793-6↗
- Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic cancer patients receiving chemotherapy. Co-author DOI 10.1007/s00464-021-08327-y↗
- The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy. Co-author DOI 10.1371/journal.pone.0267792↗
- β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer. Co-author DOI 10.3233/tub-211581↗
- Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80778-0↗
- Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89134-2↗
- Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000517835↗
- Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1415458↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hanna E. Seppänen · 8 shared papers, 2018–2024 · strength 1.37
- Paper Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival … DOI 10.1245/s10434-023-14793-6↗
- Paper The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvan… DOI 10.1371/journal.pone.0267792↗
- Paper Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal A… DOI 10.1159/000517835↗
- Caj H. Haglund · 8 shared papers, 2018–2024 · strength 1.37
- Paper Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival … DOI 10.1245/s10434-023-14793-6↗
- Paper The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvan… DOI 10.1371/journal.pone.0267792↗
- Paper Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal A… DOI 10.1159/000517835↗
- Sini Vehviläinen · 2 shared papers, 2022–2024 · strength 0.40
- Paper Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival … DOI 10.1245/s10434-023-14793-6↗
- Paper Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic… DOI 10.1007/s00464-021-08327-y↗
- Leena Kylänpää · 2 shared papers, 2022–2024 · strength 0.40
- Paper Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival … DOI 10.1245/s10434-023-14793-6↗
- Paper Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic… DOI 10.1007/s00464-021-08327-y↗
- Annika Eurola · 2 shared papers, 2021–2022 · strength 0.30
- Paper β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreat… DOI 10.3233/tub-211581↗
- Paper Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer. DOI 10.1038/s41598-021-89134-2↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.